Zentalis announces Phase 1b MUIR trial data for azenosertib plus paclitaxel in ovarian cancer

Zentalis Pharmaceuticals presented Phase 1b MUIR trial results showing 39% overall response rate and 7.3-month median PFS for azenosertib combined with paclitaxel in platinum-resistant ovarian cancer patients. The data demonstrates a manageable safety profile and supports continued development of azenosertib-taxane combinations, bolstering the company's broader indication expansion strategy beyond its core monotherapy focus.